Adrenocortical Carcinoma

Steven E. Rodgers; Douglas B. Evans; Jeffrey E. Lee; Nancy D. Perrier

doi:10.1016/j.soc.2006.05.005

Adrenocortical Carcinoma

Steven E. Rodgers, Douglas B. Evans, Jeffrey E. Lee, Nancy D. Perrier

Research output: Contribution to journal › Review article

17 Scopus citations

Abstract

ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with improvement in patient survival. Even with appropriate diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.

Original language	English (US)
Pages (from-to)	535-553
Number of pages	19
Journal	Surgical oncology clinics of North America
Volume	15
Issue number	3
DOIs	https://doi.org/10.1016/j.soc.2006.05.005
State	Published - Jul 1 2006
Externally published	Yes

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1016/j.soc.2006.05.005

Fingerprint Dive into the research topics of 'Adrenocortical Carcinoma'. Together they form a unique fingerprint.

Cite this

Rodgers, S. E., Evans, D. B., Lee, J. E., & Perrier, N. D. (2006). Adrenocortical Carcinoma. Surgical oncology clinics of North America, 15(3), 535-553. https://doi.org/10.1016/j.soc.2006.05.005

@article{3d3c0db9f154460e808eaa5d9addd033,

title = "Adrenocortical Carcinoma",

abstract = "ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with improvement in patient survival. Even with appropriate diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.",

author = "Rodgers, {Steven E.} and Evans, {Douglas B.} and Lee, {Jeffrey E.} and Perrier, {Nancy D.}",

year = "2006",

month = jul,

day = "1",

doi = "10.1016/j.soc.2006.05.005",

language = "English (US)",

volume = "15",

pages = "535--553",

journal = "Surgical Oncology Clinics of North America",

issn = "1055-3207",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Adrenocortical Carcinoma

AU - Rodgers, Steven E.

AU - Evans, Douglas B.

AU - Lee, Jeffrey E.

AU - Perrier, Nancy D.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with improvement in patient survival. Even with appropriate diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.

AB - ACC is a rare clinical entity that carries a poor prognosis; early diagnosis and complete surgical resection are associated with improvement in patient survival. Even with appropriate diagnosis and treatment, most patients will develop recurrence and succumb to ACC because of the underlying tumor biology, the difficulty of achieving a complete resection, and the lack of effective systemic therapies. Despite its many drawbacks, mitotane continues to be a mainstay in the treatment of high-risk patients with ACC, especially those with recurrent or metastatic disease. Recent findings suggest that mitotane, combined with conventional chemotherapeutic agents, may improve survival for such patients.

UR - http://www.scopus.com/inward/record.url?scp=33746378196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746378196&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2006.05.005

DO - 10.1016/j.soc.2006.05.005

M3 - Review article

C2 - 16882496

AN - SCOPUS:33746378196

VL - 15

SP - 535

EP - 553

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 3

ER -